A recent study reported poorer outcomes in patients with advanced GC and Hp positivity receiving PD-1/PD-L1 inhibitors, potentially due to an immunologically “cold” tumor phenotype dominated by suppressive myeloid and MC populations [113]. This evidence concerns the gene HP and gastric cancer.